Implication of metabolomics and transporter modulation based strategies to minimize multidrug resistance and enhance site-specific bioavailability: a needful consideration toward modern anticancer drug discovery / Megha Rachmale, Niraj Rajput, Tarang Jadav, Amit Kumar Sahu, Rakesh K. Tekade, Pinaki Sengupta
Abstract Induction of drug-metabolizing enzymes and efflux transporters (DMET) through activation of pregnane x receptor (PXR) is the primary factor involved in almost all bioavailability and drug resistance-related problems of anticancer drugs. PXR is a transcriptional regulator of many metabolizing enzymes and efflux transporters proteins like p-glycoprotein (p-gp), multidrug resistant protein 1 and 2 (MRP 1 and 2), and breast cancer resistant protein (BCRP), etc. Several anticancer drugs are potent activators of PXR receptors and can modulate the gene expression of DMET proteins. Involvement of anticancer drugs in transcriptional regulation of DMET can prompt increased metabolism and efflux of their own or other co-administered drugs, which leads to poor site-specific bioavailability and increased drug resistance. In this review, we have discussed several novel strategies to evade drug-induced PXR activation and p-gp efflux including assessment of PXR ligand and p-gp substrate at early stages of drug discovery. Additionally, we have critically discussed the chemical structure and drug delivery-based approaches to avoid PXR binding and inhibit the p-gp activity of the drugs at their target sites.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Drug metabolism reviews - 54(2022), 2, Seite 101-119 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rachmale, Megha [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Anticancer drug development |
|---|
| Umfang: |
1 Online-Ressource (19 p) |
|---|
| doi: |
10.1080/03602532.2022.2048007 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011123338 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011123338 | ||
| 003 | DE-627 | ||
| 005 | 20230713210813.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/03602532.2022.2048007 |2 doi | |
| 035 | |a (DE-627)KFL011123338 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/03602532.2022.2048007 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Rachmale, Megha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Implication of metabolomics and transporter modulation based strategies to minimize multidrug resistance and enhance site-specific bioavailability: a needful consideration toward modern anticancer drug discovery |c Megha Rachmale, Niraj Rajput, Tarang Jadav, Amit Kumar Sahu, Rakesh K. Tekade, Pinaki Sengupta |
| 264 | 1 | |c 2022 | |
| 300 | |a 1 Online-Ressource (19 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Induction of drug-metabolizing enzymes and efflux transporters (DMET) through activation of pregnane x receptor (PXR) is the primary factor involved in almost all bioavailability and drug resistance-related problems of anticancer drugs. PXR is a transcriptional regulator of many metabolizing enzymes and efflux transporters proteins like p-glycoprotein (p-gp), multidrug resistant protein 1 and 2 (MRP 1 and 2), and breast cancer resistant protein (BCRP), etc. Several anticancer drugs are potent activators of PXR receptors and can modulate the gene expression of DMET proteins. Involvement of anticancer drugs in transcriptional regulation of DMET can prompt increased metabolism and efflux of their own or other co-administered drugs, which leads to poor site-specific bioavailability and increased drug resistance. In this review, we have discussed several novel strategies to evade drug-induced PXR activation and p-gp efflux including assessment of PXR ligand and p-gp substrate at early stages of drug discovery. Additionally, we have critically discussed the chemical structure and drug delivery-based approaches to avoid PXR binding and inhibit the p-gp activity of the drugs at their target sites | ||
| 653 | |a Drug-metabolizing enzymes and efflux transporters | ||
| 653 | |a PXR receptor | ||
| 653 | |a multi drug resistance | ||
| 653 | |a site-specific bioavailability | ||
| 653 | |a Nanocarrier drug cargo | ||
| 653 | |a anticancer drug development | ||
| 700 | 1 | |a Rajput, Niraj |e verfasserin |4 aut | |
| 700 | 1 | |a Jadav, Tarang |e verfasserin |4 aut | |
| 700 | 1 | |a Sahu, Amit Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Tekade, Rakesh K. |e verfasserin |4 aut | |
| 700 | 1 | |a Sengupta, Pinaki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug metabolism reviews |d Abingdon : Taylor & Francis Group, 1972 |g 54(2022), 2, Seite 101-119 |h Online-Ressource |w (DE-627)KFL000006025 |w (DE-600)2028205-9 |w (DE-576)27387960X |x 1097-9883 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2022 |g number:2 |g pages:101-119 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/03602532.2022.2048007 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_05 | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2022 |e 2 |h 101-119 | ||